Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Reimbursement policy and androgen-deprivation therapy for prostate cancer
Vahakn B. Shahinian
,
Yong Fang Kuo
, Scott M. Gilbert
Biostatistics & Data Science
Research output
:
Contribution to journal
›
Article
›
peer-review
170
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Reimbursement policy and androgen-deprivation therapy for prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjuvant Therapy
18%
American Cancer Society
9%
Androgen Deprivation Therapy
100%
Confidence Interval
18%
Evidence-based
9%
High-grade Tumor
9%
Inappropriate Use
18%
Localized Cancer
9%
Locally Advanced Cancer
9%
Low-to-moderate
9%
Medicare Database
9%
Medicare Modernization Act
9%
Medicare Reimbursement
9%
Modified Poisson Regression
9%
Odds Ratio
18%
Poisson Regression
9%
Primary Therapy
18%
Prostate Cancer
100%
Radiation Therapy
9%
Reimbursement
9%
Reimbursement Mechanisms
100%
Substantial Change
9%
Surveillance Epidemiology
9%
Survival Benefit
18%
Year of Diagnosis
18%
Nursing and Health Professions
Adjuvant Therapy
18%
Advanced Cancer
9%
Androgen Deprivation Therapy
100%
Confidence Interval
18%
Medicare
27%
Odds Ratio
18%
Prostate Cancer
100%
Radiotherapy
9%
Reimbursement
100%
Medicine and Dentistry
Adjuvant Therapy
18%
Advanced Cancer
9%
Androgen Deprivation Therapy
100%
Cancer
9%
Malignant Neoplasm
9%
Medicare
27%
Odds Ratio
18%
Prostate Cancer
100%
Radiation Therapy
9%
Surveillance, Epidemiology, and End Results
9%
Tumor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
9%
Androgen
100%
Malignant Neoplasm
9%
Prostate Cancer
100%